Very Low-Density Lipoprotein
Very low-density lipoprotein (VLDL) is the liver's triglyceride export fleet: 30–80 nm ApoB-100 particles assembled in hepatocytes that carry endogenous fat to adipose tissue and muscle, then decay into IDL and LDL . Its secretion sets both plasma triglyceride and liver fat — why insulin resistance floods blood with VLDL.
Lipid Class Triglyceride-rich lipoprotein (endogenous transport)
Core Composition Triglyceride -rich core with cholesterol, cholesteryl esters, phospholipids; apoB-100, apoC1, apoE
Particle Size Diameter 30–80 nm; VLDL1 larger and more triglyceride-rich than VLDL2
Primary Location Assembled in the liver ; circulates in plasma
Assembly Factors Microsomal triglyceride transfer protein (MTP); ACAT2 for cholesteryl esters
Associated Conditions Hepatic steatosis; atherosclerotic cardiovascular disease
Structure & Classification
Particles measure 30–80 nanometers; some split VLDL1 (larger, more triglycerides) from VLDL2.
VLDL carries endogenous products; chylomicrons carry exogenous dietary ones.
It heads the apoB-100 lineage built on the APOB assembly line.
Metabolism & Transport
Two-step assembly: MTP transfers lipid to apolipoprotein B during translation; precursors then fuse with triglyceride droplets into mature VLDL.
ACAT2 is the sole cholesteryl ester source for VLDL and chylomicron assembly; output is controlled mainly by presecretory degradation.
Nascent VLDL (apoB-100, apoC1, apoE) picks up apoC-II and more apoE from HDL .
Lipoprotein lipase in adipose, cardiac, and skeletal-muscle capillaries removes triglycerides for storage or energy production.
CETP swaps HDL cholesteryl esters for VLDL triglycerides; the remodeled particle becomes IDL — half liver-endocytosed, half becoming LDL.
Physiological Role
VLDL moves endogenous triglycerides, phospholipids, cholesterol , and cholesteryl esters to peripheral tissues.
Lipolysis hands fatty acids to adipocytes for storage and muscle for energy.
Hepatocyte VLDL production directly impacts liver fat, exporting triglyceride that would otherwise accumulate.
Particles can ferry hydrophobic messengers like the morphogen Indian hedgehog.
Interactions
Clinical Relevance
VLDL overproduction links steatosis — which can progress to steatohepatitis and cirrhosis — with atherogenic dyslipidemia.
Elevated VLDL raises plasma triglycerides, and its remnants are atherogenic.
The LDL receptor modulates VLDL production via nascent-particle interactions — a lever on both VLDL and LDL levels.
Sources
Directory Lipids Registry Human Biology Hub